How to Adjust Insulin Dose in DKA
Start with a fixed-rate intravenous insulin infusion of 0.1 units/kg/h for moderate-to-severe DKA, then reduce to 0.05 units/kg/h when blood glucose falls below 14 mmol/L (250 mg/dL), while simultaneously starting dextrose-containing fluids to maintain glucose between 150-200 mg/dL until ketoacidosis resolves. 1
Initial Insulin Dosing
For moderate or severe DKA, the 2025 ADA guidelines recommend:
- 0.1 units/kg/h as a continuous IV infusion of short-acting insulin 1
- An optional 0.1 units/kg IV bolus of rapid-acting insulin analog may be given if there's delay in setting up the infusion 1
For mild DKA, consider:
- 0.05 units/kg/h IV insulin infusion as an alternative starting dose 1
- Or 0.1 units/kg subcutaneous rapid-acting insulin analog 1
Critical caveat: Do not start insulin if potassium is <3.5 mmol/L—correct hypokalemia first, as insulin drives potassium intracellularly and can precipitate life-threatening arrhythmias 1
Adjusting Insulin During Treatment
When Glucose Drops Below 250 mg/dL (14 mmol/L):
Reduce the insulin infusion rate to 0.05 units/kg/h 1, 2. This is a critical adjustment that reduces complications, though real-world implementation has been suboptimal with significant delays in making this change 2.
Simultaneously add dextrose-containing IV fluids (typically 5-10% dextrose in 0.9% NaCl or crystalloid) alongside continued 0.9% NaCl/crystalloid 1. This "two-bag" system allows you to maintain adequate insulin delivery to clear ketones while preventing hypoglycemia.
Target Glucose Ranges:
- DKA: Maintain glucose between 150-200 mg/dL until resolution 1
- HHS: Target glucose between 200-250 mg/dL until resolution 1
Do not stop insulin when glucose normalizes—ketoacidosis resolution lags behind glucose normalization. The goal is clearing ketones, not just lowering glucose.
Monitoring Requirements
Check electrolytes, renal function, venous pH, osmolality, and glucose every 2-4 hours until stable 1. This frequent monitoring allows timely adjustments and prevents complications like hypokalemia (which worsens with insulin therapy) and hypoglycemia.
Special Consideration: Euglycemic DKA
For euglycemic DKA (increasingly common with SGLT2 inhibitor use), traditional glucose-based protocols fail 3. These patients require:
- Fixed-rate insulin infusion (not adjusted based on glucose)
- Dextrose-containing fluids from the start to prevent hypoglycemia while clearing ketones 3
This represents a paradigm shift from traditional DKA management and requires specific protocols 3.
Common Pitfalls to Avoid
Stopping insulin too early: Continue insulin until ketoacidosis resolves (pH >7.3, bicarbonate >18 mmol/L, anion gap <12), not just when glucose normalizes 1
Delayed insulin rate reduction: When glucose drops below 250 mg/dL, there's often a significant lag (median 3.2 hours) in reducing insulin rate—this increases hypoglycemia risk 2
Inadequate potassium monitoring: Insulin drives potassium into cells; give potassium in each liter of IV fluid to maintain serum K+ between 4-5 mmol/L 1
Using sliding scale insulin alone: This reactive approach is inadequate for DKA management 4
Transition to Subcutaneous Insulin
When DKA resolves and the patient can eat:
- Calculate total daily subcutaneous insulin dose from the average insulin infused during the 12 hours before transition 4
- Example: If receiving 1.5 units/hour = 36 units/24 hours total daily dose 4
- Continue IV insulin for 1-2 hours after giving subcutaneous insulin to prevent rebound ketoacidosis 1
- Use a basal-bolus regimen (50% basal, 50% prandial) rather than sliding scale alone 4
The evidence shows that very-low-dose insulin protocols (as low as 1 unit/hour) can be effective and safe 5, though current guidelines favor weight-based dosing for standardization. The key principle is avoiding excessive glucose drops (>100 mg/dL/hour) to prevent cerebral edema risk, particularly in pediatric patients 6.